Read by QxMD icon Read

Spasticity AND dysport

Alberto Esquenazi, Stella Lee, Nathaniel Mayer, Roser Garreta, Atul Patel, Elie Elovic, Stephen Koelbel, Gerard Francisco, Iris Reuter
OBJECTIVE: The aim of the study was to report physician experience-based "real-world" treatment patterns with botulinum toxin type A in patients with stroke and traumatic brain injury. DESIGN: A prospective, multicenter, international observational registry design was used. RESULTS: Six hundred twenty-seven participants with stroke and 132 participants with traumatic brain injury were assessed and treated by 17 more experienced physicians and 12 less experienced physicians...
June 28, 2017: American Journal of Physical Medicine & Rehabilitation
Michael W O'Dell, Allison Brashear, Robert Jech, Thierry Lejeune, Philippe Marque, Djamel Bensmail, Ziyad Ayyoub, David M Simpson, Magali Volteau, Claire Vilain, Philippe Picaut, Jean Michel Gracies
BACKGROUND: AbobotulinumtoxinA has beneficial effects on spasticity and active movements in hemiparetic adults with upper limb spasticity (ULS). However, evidence-based information on optimal dosing for clinical use is limited. OBJECTIVE: To describe joint-specific dose effects of abobotulinumtoxinA in adults with ULS. DESIGN: Secondary analysis of a phase 3 study (NCT01313299). SETTING: Multicenter, international, double-blind, placebo-controlled clinical trial...
June 19, 2017: PM & R: the Journal of Injury, Function, and Rehabilitation
Christina Marciniak, Peter McAllister, Heather Walker, Allison Brashear, Steven Edgley, Thierry Deltombe, Svetlana Khatkova, Marta Banach, Fatma Gul, Claire Vilain, Philippe Picaut, Anne-Sophie Grandoulier, Jean-Michel Gracies
OBJECTIVE: To assess the efficacy and safety of abobotulinumtoxinA in adults with upper limb spasticity previously treated with botulinum toxin A (BoNT-A). DESIGN: A post hoc analysis from a Phase 3, prospective, double-blind, randomized, placebo-controlled study (NCT01313299). SETTING: A total of 34 neurology or rehabilitation clinics in 9 countries. PARTICIPANTS: Adults aged 18-80 years with hemiparesis, ≥6 months after stroke or traumatic brain injury...
June 16, 2017: PM & R: the Journal of Injury, Function, and Rehabilitation
Yahiya Y Syed
AbobotulinumtoxinA (Dysport(®)) is currently the only botulinum toxin A formulation approved by the US FDA for the treatment of lower limb spasticity in pediatric patients aged ≥2 years. Intramuscular abobotulinumtoxinA was approved based on the results of a pivotal phase 3 trial in children with lower limb spasticity due to cerebral palsy. In this trial, a single treatment cycle with abobotulinumtoxinA 10-15 U/kg/leg injected into the gastrocnemius and soleus muscles significantly improved ankle plantar flexor muscle tone (primary endpoint), with abobotulinumtoxinA recipients showing a significant response to treatment relative to placebo...
August 2017: Paediatric Drugs
Jean-Michel Gracies, Michael O'Dell, Michele Vecchio, Peter Hedera, Serdar Kocer, Monika Rudzinska-Bar, Bruce Rubin, Sofiya L Timerbaeva, Anna Lusakowska, François Constant Boyer, Anne-Sophie Grandoulier, Claire Vilain, Philippe Picaut
INTRODUCTION: The efficacy of single injections of abobotulinumtoxinA (Dysport) is established in adults with upper limb spasticity. In this study we assessed the effects of repeated injections of abobotulinumtoxinA over 1 year. METHODS: Patients (n = 258, safety population) received 500 U, 1,000 U, or 1,500 U (1,500-U dose included 500-U shoulder injections) for up to 4 or 5 treatment cycles. Assessments included treatment-emergent adverse events (TEAEs), muscle tone, passive and active range of motion (XV1, XA ), angle of catch (XV3 ), Disability Assessment Scale (DAS) score, Modified Frenchay Scale (MFS) score, and Physician Global Assessment (PGA) score...
June 7, 2017: Muscle & Nerve
Dirk Dressler, Fereshte Adib Saberi
BACKGROUND: AbobotulinumtoxinA (Dysport®) was distributed for many years in vials containing 500MU (D500). Recently a new 300MU vial (D300) was additionally introduced (introduction). We wanted to explore whether more differentiated package sizes allow for more economic use of Dysport® in a large neurological botulinum toxin (BT) outpatient clinic. METHODS: The study followed a retrospective chart review design based on our digital BT therapy data bank. All patients receiving Dysport® exclusively in a constant dose during the observation period (introduction ± 7 months) were included...
2017: Journal of Clinical Movement Disorders
Samira Lahrabli, Herman Azanmasso, Fatima Lmidmani, Abdellatif El Fatimi
OBJECTIVE: Intramuscular injection of botulinum toxin can be painful for some patients. This may be due either to a broken skin, stimulation for locating, or injecting the product. The objective of this study was to see the clinical impact of pain on injection. MATERIAL/PATIENTS AND METHODS: Retrospective study of 15 patients (6 M/9 W), average age was 31 years (11-75 years). The patients had spasticity of MS in 40% and a MI spasticity in 60%. The treatment was basic Dysport...
September 2016: Annals of Physical and Rehabilitation Medicine
Aurélie Rochefolle, Emmanuelle Carré, Aurélie Rochefolle, Marie Callies de Sallies, Florence Durand, Catherine Rioufol, Jacques Luaute, Gilles Rode
OBJECTIVE: Botulinum toxins are often prescribed in aftercare and neurological rehabilitation services. In our hospital, they are exponentially used in the treatment of spasticity. The objective of this study is to make an assessment of their use over the period 2012-2015. MATERIAL/PATIENTS AND METHODS: All the botulinum toxin prescriptions are followed by the chemists. A traceability form allows to collect information about the patient, the prescriber, the medicine and its dose, the cost, and the indication...
September 2016: Annals of Physical and Rehabilitation Medicine
Dennis Matthews, George C Camba, Ignacio Pascual-Pascual, Ann H Tilton, Mark Gormley, Adnan Mahmood, Philippe Picaut, Daniel Snyder, Mauricio R Delgado
No abstract text is available yet for this article.
September 2016: PM & R: the Journal of Injury, Function, and Rehabilitation
Christina Marciniak, Fatma Gul, Ziyad Ayyoub, David M Simpson, Heather W Walker, Michael Wimmer, Claire Vilain, Jean-Michel Graciès
No abstract text is available yet for this article.
September 2016: PM & R: the Journal of Injury, Function, and Rehabilitation
Fatma Gul, Michael O'Dell, Robert Jech, Marta Banach, Claire Vilain, Anne-Sophie As Grandoulier, Jean-Michel Germain, Jean-Michel Graciès
No abstract text is available yet for this article.
September 2016: PM & R: the Journal of Injury, Function, and Rehabilitation
Francesco Scaglione
Botulinum neurotoxin has revolutionized the treatment of spasticity and is now administered worldwide. There are currently three leading botulinum neurotoxin type A products available in the Western Hemisphere: onabotulinum toxin-A (ONA) Botox(®), abobotulinum toxin-A (ABO), Dysport(®), and incobotulinum toxin A (INCO, Xeomin(®)). Although the efficacies are similar, there is an intense debate regarding the comparability of various preparations. Here we will address the clinical issues of potency and conversion ratios, as well as safety issues such as toxin spread and immunogenicity, to provide guidance for BoNT-A use in clinical practice...
March 4, 2016: Toxins
Yu N Ponomarenko, S V Vasenko, A M Nenko
The study analyses results of treatment of 196 patients, with cerebral palsy, which underwent a course of health-resort treatment is performed. Past medical history of patients for the last 10 years was also analysed. It was found that the use of botulin toxin <A> (BT-A) <Dysport®> as a part of complex rehabilitation of the patients significantly improved the effectiveness of the treatment. It was determined that the reasons of the lack of spasticity reduce are caused by degeneration of the muscles...
August 2015: Voenno-medit︠s︡inskiĭ Zhurnal
S E Khat'kova, D R Khasanova, L A Korenko, L N Antipova, L P Shperling, D V Popov, D V Pokhabov, E V Poznyakova
AIM: To assess the efficacy of Botulinum toxin type A (BoNT-A) injections in routine practice. MATERIAL AND METHODS: An international, post-marketing, multi-center, observational, prospective, longitudinal study included patients ≥18 years with poststroke upper-limb spasticity in whom a decision to inject BoNT-A had already been made, and who had no previous treatment with BoNT-A or BoNT-B within the last 12 weeks. The responder rate was assessed by the patient-centered goal attainment scaling (GAS)...
2015: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
Z A Zalialova
The most frequent causes of disability of patients with neurological diseases are motor disorders in the upper motor neuron lesion caused by the damage of the brain and/or the spinal cord that resulted in the formation of spastic paresis and paralysis. The correct understanding of the pathophysiological basis of clinical presentations of the upper motor neuron lesion will allow to chose the most adequate and prognostically successful methods of treatment. Currently, treatment with botulotoxin can be considered as such a method...
2014: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
Mark de Niet, Susanne T de Bot, Bart P C van de Warrenburg, Vivian Weerdesteyn, Alexander C Geurts
OBJECTIVE: Although calf muscle spasticity is often treated with botulinum toxin type-A, the effects on balance and gait are ambiguous. Hereditary spastic paraplegia is characterized by progressive spasticity and relatively mild muscle weakness of the lower limbs. It is therefore a good model to evaluate the functional effects of botulinum toxin type-A. DESIGN: Explorative pre-post intervention study. SUBJECTS: Fifteen subjects with pure hereditary spastic paraplegia...
February 2015: Journal of Rehabilitation Medicine
F de Andrés-Nogales, A Morell, J Aracil, C Torres, I Oyagüez, M A Casado
OBJECTIVE: To estimate treatment costs of blepharospasm, cervical dystonia(CD), upper limb spasticity (ULS) and spasticity in children with cerebral palsy (SCCP) with botulinum neurotoxin type A (BoNT-A) in Spain. METHOD: Annual BoNT-A treatment costs were calculated (2013 ex-factory price () applying RDL 8/2010 and RDL 9/2011 deductions), based on initial dose (id), average dose (ad) and maximum dose (md) according to Summary of Product Characteristics of Botox® (100U/50U), Dysport®(500U) and Xeomin® (100U) and considering the use of complete vials...
May 2014: Farmacia Hospitalaria
Mohsen Bahmani Kashkouli, Afsaneh Amani, Mansooreh Jamshidian-Tehrani, Sahar Yousefi, Anis Alsadat Jazayeri
PURPOSE: To report the method and results of 18-point Abobotulinum toxin A (ABO-BTA, Dysport) upper face rejuvenation on 845 subjects. METHODS: In a retrospective chart review, all subjects (the first cycle of injection) with ABO-BTA upper face rejuvenation from 2003 to 2009 were included. Excluded were subjects with facial spastic disorders, injection after upper face lifting, and aberrant regeneration of facial nerves. Upper face rejuvenation included 18 points of injection at forehead creases (4), frown lines (5), bunny line (1), crow's feet (4 on both sides), and lower eyelid crease (4 on both sides)...
May 2014: Ophthalmic Plastic and Reconstructive Surgery
Wolfgang H Jost, Harald Hefter, Andrea Reissig, Katja Kollewe, Joerg Wissel
The current practice in Germany and Austria, and the safety and efficacy of botulinum toxin type A (BoNT-A; Dysport) in the treatment of patients with post-stroke arm spasticity (with no fixed upper-limb contractures), were assessed in this observational prospective non-interventional study. One treatment cycle was documented with assessments at baseline, approximately week 4 (optional), and approximately week 12. Pattern of spasticity, treatment goal, safety and efficacy were recorded. Overall response and goal achievement was rated on a 4-point scale ('no goal achievement', 'goal achievement', 'good goal achievement', 'best goal achievement')...
February 15, 2014: Journal of the Neurological Sciences
Mohammad Yazdchi, Zahra Ghasemi, Hanieh Moshayedi, Reza Rikhtegar, Somayeh Mostafayi, Hale Mikailee, Safa Najmi
BACKGROUND: This study evaluated the efficacy of focal intramuscular injection of botulinum (BoNT) toxin type A in comparison with oral tizanidine (TZD) in treatment of post-stroke upper limb spasticity. METHODS: This was a double-blinded randomized clinical trial that recruited 68 patients with post-stroke upper limb spasticity. Thirty-four patients received BoNT (Dysport(®)) injections in affected muscles of upper limb at the baseline and week 12. Thirty-four patients were treated with tizanidine (Sirdalude) by gradual increase in dosage of 2mg/week to reach maximum 24mg at week 12...
2013: Iranian Journal of Neurology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"